| Authors: |
Oziolor E; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Xue L; Machine Learning and Computational Sciences, Pfizer Inc., Cambridge, MA, USA., Pelletier D; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Capunitan D; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Kimoto E; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, USA., Federspiel JD; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA.; Drug Safety Research and Development, Pfizer, Inc, Andover, MA, USA., Sheehan M; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Arat S; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Newman L; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Lee G; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Qian J; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Kumpf S; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Lanz TA; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA., Martin M; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA. matthew.martin@pfizer.com., Mathialagan N; Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA. nagappan.mathialagan@pfizer.com. |
